Neurocrine Biosciences Inc

NASDAQ:NBIXUnited States

Today

Show headlines and story abstract

• Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours, from 31 minutes ago by MT Newswires

  31 minutes ago by MT Newswires
  Companies Mentioned: NBIX
  05:45 PM EDT, 04/30/2024 (MT Newswires) -- Neurocrine Biosciences (NBIX) said late Tuesday the US Food and Drug Administration approved the Ingrezza Sprinkle capsules to treat adults with tardive dyskinesia and chorea related to Huntington's disease...

• Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA(R) SPRINKLE (valbenazine) Capsules, from 1 hour ago by PR Newswire

  1 hour ago by PR Newswire
  Companies Mentioned: NBIX

  Neurocrine Biosciences, Inc.(Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA(R) SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA(R) (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.1 INGREZZA SPRINKLE provides an alternative administration option for those who experience dysphagia or have difficulty swallowing.

• Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA(R) SPRINKLE (valbenazine) Capsules, from 1 hour ago by Dow Jones

  1 hour ago by Dow Jones
  Companies Mentioned: NBIX
  
  The most common side effect of INGREZZA or INGREZZA SPRINKLE in people with tardive dyskinesia are sleepiness and tiredness.
  
  The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with chorea associated with Huntington's disease include sleepiness and tiredness, raised itchy red areas on your skin (hives), rash, and trouble getting to sleep or staying asleep.